BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tvingsholm SA, Dehlendorff C, Østerlind K, Friis S, Jäättelä M. Proton pump inhibitor use and cancer mortality. Int J Cancer 2018;143:1315-26. [PMID: 29658114 DOI: 10.1002/ijc.31529] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Hálfdánarson ÓÖ, Pottegård A, Lund SH, Ogmundsdottir MH, Ogmundsdottir HM, Zoega H. Use of proton pump inhibitors and mortality among Icelandic patients with prostate cancer. Basic Clin Pharmacol Toxicol 2020;126:484-91. [PMID: 31872571 DOI: 10.1111/bcpt.13379] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
2 Patel A, Spychalski P, Antoszewska M, Regula J, Kobiela J. Proton pump inhibitors and colorectal cancer: A systematic review. World J Gastroenterol 2021; 27(44): 7716-7733 [PMID: 34908809 DOI: 10.3748/wjg.v27.i44.7716] [Reference Citation Analysis]
3 Meriggi F. Controversial link between proton pump inhibitors and anticancer agents: review of the literature. Tumori 2021;:3008916211025091. [PMID: 34159850 DOI: 10.1177/03008916211025091] [Reference Citation Analysis]
4 Wang X, Liu Q, Halfdanarson ÓÖ, Zoega H, Sadr-Azodi O, Engstrand L, Fall K, Brusselaers N. Proton pump inhibitors and survival in patients with colorectal cancer: a Swedish population-based cohort study. Br J Cancer 2021. [PMID: 34253872 DOI: 10.1038/s41416-021-01480-0] [Reference Citation Analysis]
5 Wilson JA, Stocken DD, Watson GC, Fouweather T, McGlashan J, MacKenzie K, Carding P, Karagama Y, Harries M, Ball S, Khwaja S, Costello D, Wood R, Lecouturier J, O'Hara J. Lansoprazole for persistent throat symptoms in secondary care: the TOPPITS RCT. Health Technol Assess 2021;25:1-118. [PMID: 33492208 DOI: 10.3310/hta25030] [Reference Citation Analysis]
6 Ayyagari S, Tan MC, Liu Y, El-Serag HB, Thrift AP. Use of Acid-Suppressant Medications After Diagnosis Increases Mortality in a Subset of Gastrointestinal Cancer Patients. Dig Dis Sci 2020;65:2691-9. [PMID: 31802383 DOI: 10.1007/s10620-019-05984-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Indini A, Petrelli F, Tomasello G, Rijavec E, Facciorusso A, Grossi F, Ghidini M. Impact of Use of Gastric-Acid Suppressants and Oral Anti-Cancer Agents on Survival Outcomes: A Systematic Review and Meta-Analysis. Cancers (Basel). 2020;12. [PMID: 32325628 DOI: 10.3390/cancers12040998] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
8 Cholin L, Ashour T, Mehdi A, Taliercio JJ, Daou R, Arrigain S, Schold JD, Thomas G, Nally J, Nakhoul NL, Nakhoul GN. Proton-pump inhibitor vs. H2-receptor blocker use and overall risk of CKD progression. BMC Nephrol 2021;22:264. [PMID: 34266395 DOI: 10.1186/s12882-021-02449-0] [Reference Citation Analysis]
9 Santos-Pereira C, Rodrigues LR, Côrte-Real M. Emerging insights on the role of V-ATPase in human diseases: Therapeutic challenges and opportunities. Med Res Rev 2021;41:1927-64. [PMID: 33483985 DOI: 10.1002/med.21782] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Zheng T, Jäättelä M, Liu B. pH gradient reversal fuels cancer progression. The International Journal of Biochemistry & Cell Biology 2020;125:105796. [DOI: 10.1016/j.biocel.2020.105796] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
11 Brown JP, Tazare JR, Williamson E, Mansfield KE, Evans SJ, Tomlinson LA, Bhaskaran K, Smeeth L, Wing K, Douglas IJ. Proton pump inhibitors and risk of all-cause and cause-specific mortality: A cohort study. Br J Clin Pharmacol 2021;87:3150-61. [PMID: 33393677 DOI: 10.1111/bcp.14728] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Li M, Zeng C, Yao J, Ge Y, An G. The association between proton pump inhibitors use and clinical outcome of patients receiving immune checkpoint inhibitors therapy. Int Immunopharmacol 2020;88:106972. [PMID: 33182025 DOI: 10.1016/j.intimp.2020.106972] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
13 Harguindey S, Alfarouk K, Polo Orozco J, Fais S, Devesa J. Towards an Integral Therapeutic Protocol for Breast Cancer Based upon the New H+-Centered Anticancer Paradigm of the Late Post-Warburg Era. Int J Mol Sci 2020;21:E7475. [PMID: 33050492 DOI: 10.3390/ijms21207475] [Reference Citation Analysis]